Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
NCT ID NCT06810960
First seen Apr 21, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling, small bleeds, and larger hemorrhages. Researchers will use real-world data from a national registry. The goal is to understand risks in everyday medical practice, not to test if the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eisai Trial Site #1
RECRUITINGNutley, New Jersey, 07110, United States
Conditions
Explore the condition pages connected to this study.